COVID-19 vaccine Archives | Page 17 of 19

Home / Posts tagged COVID-19 vaccine (Page 17)

Novavax Provides Phase 3 COVID-19 Vaccine Clinical Development Update

GAITHERSBURG, Md., Oct. 27 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced updates on its Phase 3 clinical development program of NVX-CoV2373, its COVID-19 vaccine candidate. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant. The Company [...]

Novavax to Present COVID-19 Vaccine Data at World Vaccine Congress Europe 2020

GAITHERSBURG, Md., Oct. 20 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn, M.D, President of Research & Development, will present on NVX-CoV2373, the Company’s COVID-19 vaccine, at the 2020 World Vaccine Congress Europe. The Congress takes place virtually October 19 [...]

Novavax Appoints Leadership Team to Advance NanoFlu Through Regulatory Licensure

GAITHERSBURG, Md., Oct. 13 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX) Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the formation of a leadership team to advance NanoFlu to regulatory licensure and the promotion of Russell (Rip) Wilson, J.D./M.B.A., to Executive Vice President and the newly-created [...]

Joining Forces Against SARS-CoV-2: Rentschler Biopharma Contributes to Manufacturing of COVID-19 mRNA Vaccine

LAUPHEIM, GERMANY and MILFORD, MA, USA, Oct. 12 (Korea Bizwire) – Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced an agreement to serve as CDMO partner for BioNTech. As an initial project, Rentschler Biopharma will be responsible for key aspects of cGMP (current good manufacturing practice) drug [...]

Korean Air to Secure Additional Storage for Coronavirus Vaccine

SEOUL, Oct. 8 (Korea Bizwire) — Korean Air Lines Co. announced Wednesday that it will secure additional cool cargo centers at Incheon International Airport next year to ensure safe shipping of coronavirus vaccines. The country’s top flag carrier currently owns a 1,292 square meter refrigerated warehouse at Incheon International Airport, that is capable of storing [...]

Novavax to Participate in Upcoming Conferences

GAITHERSBURG, Md., Oct. 5 (Korea Bizwire) — Novavax Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in four upcoming investor and industry conferences. Novavax’ COVID-19 vaccine candidate, NVX-CoV2373, is expected to be discussed in each conference. Maryland Life Sciences Bio Innovation Conference Date: [...]

Informa Pharma Intelligence Launches New Pulse Report: Clinical Trials & the COVID-19 Vaccine

LONDON, Oct. 1 (Korea Bizwire) – Informa Pharma Intelligence, the global business intelligence provider for the biopharma industry, today released its “Pulse Report: Clinical Trials & the COVID-19 Vaccine” study which uncovered American sentiment and confidence around COVID-19 vaccine clinical trials. According to the data, more than 1 in 3 (35%) Americans don’t trust how quickly the COVID-19 [...]

Novavax to Present COVID-19, Influenza and RSV Candidate Vaccine Data at World Vaccine Congress Washington 2020

GAITHERSBURG, Md., Sept. 28 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will present on its lead vaccine candidates, NVX-CoV2373, NanoFlu™ and ResVax™, the Company’s COVID-19, influenza and respiratory syncytial virus (RSV) vaccines. The presentations are part of the 2020 [...]

Novavax Initiates Phase 3 Efficacy Trial of COVID-19 Vaccine in the United Kingdom

GAITHERSBURG, Md., Sept. 24 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has initiated its first Phase 3 study to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. The trial is being conducted in the United [...]

Novavax Announces COVID-19 Vaccine Manufacturing Agreement with Serum Institute of India, Increasing Novavax’ Global Production Capacity to Over 2 Billion Doses Annually

GAITHERSBURG, Md., Sept. 15 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced an amendment to its existing agreement with Serum Institute of India Private Limited (SIIPL) under which SIIPL will also manufacture the antigen component of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate. With this [...]